Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Adagrasib
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Mirati Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Krazati (adagrasib), is being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors. Lung cancer is one of the world’s most widespread cancers.
Brand Name : Krazati
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Adagrasib
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Mirati Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Neuron23
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 in...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Neuron23
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement, QIAGEN will develop a diagnostic assay that can detect the Denovo Genomic Marker 1 (DGM1) in DLBCL patients, a biomarker discovered by Denovo that predicts the responsiveness to DB102, also known as enzastaurin.
Brand Name : Kinenza
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 09, 2021
Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Navicixizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : OncXerna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
QIAGEN and OncXerna Therapeutics Sign Diagnostic Agreements
Details : QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab.
Brand Name : OMP-305B83
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Navicixizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : OncXerna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : QIAGEN’s therascreen KRAS Kit was used to support the CodeBreaK 100 clinical trial of sotorasib and the expansion of the Kit’s CDx claims to include identification of the KRAS G12C mutation in NSCLC samples has been co-approved with LUMAKRAS by the F...
Brand Name : Lumakras
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2021
Lead Product(s) : Adagrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Mirati Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : QIAGEN is developing a tissue-based companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor ...
Brand Name : MRTX849
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : Adagrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Mirati Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VGX-3100
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inovio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associat...
Brand Name : VGX-3100
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 24, 2021
Lead Product(s) : VGX-3100
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inovio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BNT113,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : QIAGEN and BioNTech to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections.
Brand Name : BNT113
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 18, 2020
Lead Product(s) : BNT113,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2020
LOOKING FOR A SUPPLIER?